Cargando…

Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis

PURPOSE: Increased lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and Rho kinase activity may be associated with atherosclerosis. The principal aim of this study was to examine whether darapladib (a selective Lp-PLA2 inhibitor) could reduce the elevated Lp-PLA2 and Rho kinase activity in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Juan, Xu, Dong-Ling, Liu, Xiao-Bo, Bi, Shao-jie, Zhao, Tong, Sui, Shu-Jian, Ji, Xiao-Ping, Lu, Qing-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740522/
https://www.ncbi.nlm.nih.gov/pubmed/26847282
http://dx.doi.org/10.3349/ymj.2016.57.2.321
_version_ 1782413863958872064
author Zhang, Juan
Xu, Dong-Ling
Liu, Xiao-Bo
Bi, Shao-jie
Zhao, Tong
Sui, Shu-Jian
Ji, Xiao-Ping
Lu, Qing-Hua
author_facet Zhang, Juan
Xu, Dong-Ling
Liu, Xiao-Bo
Bi, Shao-jie
Zhao, Tong
Sui, Shu-Jian
Ji, Xiao-Ping
Lu, Qing-Hua
author_sort Zhang, Juan
collection PubMed
description PURPOSE: Increased lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and Rho kinase activity may be associated with atherosclerosis. The principal aim of this study was to examine whether darapladib (a selective Lp-PLA2 inhibitor) could reduce the elevated Lp-PLA2 and Rho kinase activity in atherosclerosis. MATERIALS AND METHODS: Studies were performed in male Sprague-Dawley rats. The atherosclerosis rats were prepared by feeding them with a high-cholesterol diet for 10 weeks. Low-dose darapladib (25 mg·kg(-1)·d(-1)) and high-dose darapladib (50 mg·kg(-1)·d(-1)) interventions were then administered over the course of 2 weeks. RESULTS: The serum levels of triglycerides, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), high-sensitivity C-reactive protein (hs-CRP), and Lp-PLA2, significantly increased in atherosclerosis model groups, as did Rho kinase activity and cardiomyocyte apoptosis (p<0.05 vs. sham group), whereas nitric oxide (NO) production was reduced. Levels of TC, LDL-C, CRP, Lp-PLA2, and Rho kinase activity were respectively reduced in darapladib groups, whereas NO production was enhanced. When compared to the low-dose darapladib group, the reduction of the levels of TC, LDL-C, CRP, and Lp-PLA2 was more prominent in the high-dose darapladib group (p<0.05), and the increase of NO production was more prominent (p<0.05). Cardiomyocyte apoptosis of the high-dose darapladib group was also significantly reduced compared to the low-dose darapladib group (p<0.05). However, there was no significant difference in Rho kinase activity between the low-dose darapladib group and the high-dose darapladib group (p>0.05). CONCLUSION: Darapladib, a Lp-PLA2 inhibitor, leads to cardiovascular protection that might be mediated by its inhibition of both Rho kinase and Lp-PLA2 in atherosclerosis.
format Online
Article
Text
id pubmed-4740522
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-47405222016-03-01 Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis Zhang, Juan Xu, Dong-Ling Liu, Xiao-Bo Bi, Shao-jie Zhao, Tong Sui, Shu-Jian Ji, Xiao-Ping Lu, Qing-Hua Yonsei Med J Original Article PURPOSE: Increased lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and Rho kinase activity may be associated with atherosclerosis. The principal aim of this study was to examine whether darapladib (a selective Lp-PLA2 inhibitor) could reduce the elevated Lp-PLA2 and Rho kinase activity in atherosclerosis. MATERIALS AND METHODS: Studies were performed in male Sprague-Dawley rats. The atherosclerosis rats were prepared by feeding them with a high-cholesterol diet for 10 weeks. Low-dose darapladib (25 mg·kg(-1)·d(-1)) and high-dose darapladib (50 mg·kg(-1)·d(-1)) interventions were then administered over the course of 2 weeks. RESULTS: The serum levels of triglycerides, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), high-sensitivity C-reactive protein (hs-CRP), and Lp-PLA2, significantly increased in atherosclerosis model groups, as did Rho kinase activity and cardiomyocyte apoptosis (p<0.05 vs. sham group), whereas nitric oxide (NO) production was reduced. Levels of TC, LDL-C, CRP, Lp-PLA2, and Rho kinase activity were respectively reduced in darapladib groups, whereas NO production was enhanced. When compared to the low-dose darapladib group, the reduction of the levels of TC, LDL-C, CRP, and Lp-PLA2 was more prominent in the high-dose darapladib group (p<0.05), and the increase of NO production was more prominent (p<0.05). Cardiomyocyte apoptosis of the high-dose darapladib group was also significantly reduced compared to the low-dose darapladib group (p<0.05). However, there was no significant difference in Rho kinase activity between the low-dose darapladib group and the high-dose darapladib group (p>0.05). CONCLUSION: Darapladib, a Lp-PLA2 inhibitor, leads to cardiovascular protection that might be mediated by its inhibition of both Rho kinase and Lp-PLA2 in atherosclerosis. Yonsei University College of Medicine 2016-03-01 2016-01-28 /pmc/articles/PMC4740522/ /pubmed/26847282 http://dx.doi.org/10.3349/ymj.2016.57.2.321 Text en © Copyright: Yonsei University College of Medicine 2016 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zhang, Juan
Xu, Dong-Ling
Liu, Xiao-Bo
Bi, Shao-jie
Zhao, Tong
Sui, Shu-Jian
Ji, Xiao-Ping
Lu, Qing-Hua
Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
title Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
title_full Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
title_fullStr Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
title_full_unstemmed Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
title_short Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis
title_sort darapladib, a lipoprotein-associated phospholipase a2 inhibitor, reduces rho kinase activity in atherosclerosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740522/
https://www.ncbi.nlm.nih.gov/pubmed/26847282
http://dx.doi.org/10.3349/ymj.2016.57.2.321
work_keys_str_mv AT zhangjuan darapladibalipoproteinassociatedphospholipasea2inhibitorreducesrhokinaseactivityinatherosclerosis
AT xudongling darapladibalipoproteinassociatedphospholipasea2inhibitorreducesrhokinaseactivityinatherosclerosis
AT liuxiaobo darapladibalipoproteinassociatedphospholipasea2inhibitorreducesrhokinaseactivityinatherosclerosis
AT bishaojie darapladibalipoproteinassociatedphospholipasea2inhibitorreducesrhokinaseactivityinatherosclerosis
AT zhaotong darapladibalipoproteinassociatedphospholipasea2inhibitorreducesrhokinaseactivityinatherosclerosis
AT suishujian darapladibalipoproteinassociatedphospholipasea2inhibitorreducesrhokinaseactivityinatherosclerosis
AT jixiaoping darapladibalipoproteinassociatedphospholipasea2inhibitorreducesrhokinaseactivityinatherosclerosis
AT luqinghua darapladibalipoproteinassociatedphospholipasea2inhibitorreducesrhokinaseactivityinatherosclerosis